Loading
Give venetoclax for 7 or 14 days per cycle instead of 28 to cut infections and low blood counts without losing the benefit.
The idea is to give venetoclax for 7 or 14 days per 28-day cycle, rather than continuously, when combined with azacitidine or oral decitabine-cedazuridine in acute myeloid leukaemia patients unfit for intensive chemotherapy. Cytopenias and infections are the main cause of early death on venetoclax-azacitidine, marrow blasts clear within two weeks, and continued exposure mainly suppresses normal blood cell production. Retrospective and small prospective series show similar remission rates with shorter courses, against the 28-day schedule of VIALE-A. The hypothesis is that 14 days per cycle is non-inferior for overall survival with less severe infection; the test is a randomised non-inferiority trial, addressing the wrong-doses and older-patient bottlenecks.
VIALE-A turned a palliative regimen into one that produces remission in two-thirds of older AML patients and is now the reference treatment for anyone not fit for intensive chemotherapy. It shifted the field towards lower-intensity targeted combinations and opened the door to adding FLT3, IDH and menin inhibitors to the backbone. Cure remains uncommon and most patients relapse within two years.
Azacitidine became the standard low-intensity treatment for older or unfit patients with AML and the control arm for later trials; venetoclax plus azacitidine (VIALE-A) now supersedes azacitidine alone where available.
One of the most cited trial reports Europe PMC returns for Azacitidine in Acute myeloid leukaemia, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Decitabine + cedazuridine (oral), VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, VIALE-A, Acute myeloid leukaemia in older or unfit patients.
Shares AZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts, Acute myeloid leukaemia in older or unfit patients, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Venetoclax, Acute myeloid leukaemia.
Shares VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, VIALE-A, Venetoclax, Acute myeloid leukaemia.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Venetoclax, Acute myeloid leukaemia.
Shares VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, Acute myeloid leukaemia in older or unfit patients, Azacitidine, Venetoclax.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Venetoclax, Acute myeloid leukaemia.
Shares VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy, Azacitidine, Venetoclax, Acute myeloid leukaemia.